Abiopharma

🔍 Peters Malte (Executive)

Company: Tango Therapeutics, Inc. (TNGX)

Report Date: 2026-01-08

Detailed Transactions and Holdings:

• Acquired 350,000 shares of Common Stock (Direct)
  Date: 2026-01-08 | Code: A | equity_swap_involved: false | shares_owned_after: 367,500.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 1,650,000 shares of Stock Option (Right to Buy) at $11.06 per share (Derivative)
  Date: 2026-01-08 | Code: A | Expires: 2036-01-08 | equity_swap_involved: false | shares_owned_after: 1,650,000.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 33% on February 1, 2027, 33% on February 14, 2028 and 34% on February 12, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
• F2: This option shall vest and become exercisable over a four-year period, with 25% vesting on January 8, 2027 and the remaining option shares vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.